| Literature DB >> 31222089 |
José Ramos-Vivas1, Itziar Chapartegui-González1, Marta Fernández-Martínez2, Claudia González-Rico3, Jesús Fortún4, Rosa Escudero4, Francesc Marco5, Laura Linares6, Miguel Montejo7, Maitane Aranzamendi8, Patricia Muñoz9, Maricela Valerio9, Jose María Aguado10, Elena Resino10, Irene Gracia Ahufinger11, Aurora Paz Vega12, Luis Martínez-Martínez2,11, María Carmen Fariñas13,14.
Abstract
Solid organ transplant (SOT) recipients are especially at risk of developing infections by multidrug resistant bacteria (MDR). In this study, the biofilm-forming capability of 209 MDR strains (Escherichia coli n = 106, Klebsiella pneumoniae n = 78, and Enterobacter spp. n = 25) isolated from rectal swabs in the first 48 hours before or after kidney (93 patients), liver (60 patients) or kidney/pancreas transplants (5 patients) were evaluated by using a microplate assay. Thirty-nine strains were isolated before transplant and 170 strains were isolated post-transplant. Overall, 16% of E. coli strains, 73% of K. pneumoniae strains and 4% Enterobacter strains showed moderate or strong biofilm production. Nine strains isolated from infection sites after transplantation were responsible of infections in the first month. Of these, 4 K. pneumoniae, 1 E. coli and 1 Enterobacter spp. strains isolated pre-transplant or post-transplant as colonizers caused infections in the post-transplant period. Our results suggest that in vitro biofilm formation could be an important factor for adhesion to intestine and colonization in MDR K. pneumoniae strains in SOT recipients, but this factor appears to be less important for MDR E. coli and Enterobacter spp.Entities:
Mesh:
Year: 2019 PMID: 31222089 PMCID: PMC6586660 DOI: 10.1038/s41598-019-45060-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Distribution of antibiotic resistance genes in Enterobacteriaceae strains.
| Mechanisms of resistance to extended-spectrum β-lactams and carbapenems | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Species (n° strains) | AmpC-hyperproducing (16) | ||||||||||
| 50 (47.2%) | 1 (0.9%) | 33 (31.1%) | 2 (1.9%) | 15 (14.1%) | 2 (1.9%) | — | — | — | 2 (1.9%) | 1 (0.9%) | |
| 39 (50.0%) | — | 3 (3.8%) | 1 (1.3%) | 3 (3.8%) | — | 2 (2.6%) | 3 (3.8%) | 2 (2.6%) | 25 (32.0%) | — | |
| 1 (4.0%) | — | 7 (28.0%) | — | — | 14 (56.0%) | 1 (4.0%) | 2 (8.0%) | — | — | — | |
Isolated from transplant patients.
Figure 1Quantification of biofilm formation was performed after Crystal Violet extraction and measurement (OD620). Values are presented as mean ± standard deviation of four independent experiments.
Figure 2Biofilm formation by the six Enterobacteriaceae strains responsible of infections. These strains were compared with their respective isolates pre-transplant (Pre-T) or isolates from rectal swabs post-transplant (colonizing strains, C-S). Up: wells were stained with Crystal Violet inside 24-well plates. Source of isolation during infections is indicated. Down: representative examples of CLSM images of selected strains after biofilm formation. Bacteria were stained with the BacLight LIVE/DEAD viability kit. Live cells fluoresce in green with Syto 9 dye and dead cells are stained red with propidium iodide. Original magnification: ×200.
Figure 3PFGE profiles of isolates from rectal swabs obtained pre-transplant or isolates from rectal swabs post-transplant (colonizing strains, C-S) and from infection-related strains (I).
Characteristics of the eight strains responsible for infection of transplant recipients.
| Strain | post-transplant infection | Transplant | Species | aAntibiotic resistance | Resistance genes | bHA | cBiofilm |
|---|---|---|---|---|---|---|---|
| 25 | — | Renal | AMX, AMC, AZT, CAZ, CIP, CTX, FEP, FOS, GN, NET, PIP, SXT, TO, TZP | — | SB | ||
| 27 | Renal | AMX, AMC, AZT, CAZ, CTX, FEP, GN, NET, PIP, SXT, TGC, TO, TZP | — | SB | |||
| 120 | — | Renal | AMX, AMC, CTX, FOS, FOX, NAL, PIP, TGC, TZP | — | NB | ||
| 121 | Renal | AMX, AMC, CTX, FOS, FOX, NAL, PIP, TGC, TZP | — | NB | |||
| 158 | — | Hepatic | AMX, AMC, AZT, CAZ, CIP CTX, LEV, NAL, PIP, SXT | — | MB | ||
| 163 | Hepatic | AMX, AMC, AZT, CAZ, CIP CTX, FEP, FOX, LEV, NAL, PIP, SXT, TGC | — | SB | |||
| 168 | — | Hepatic | AMX, AMC, AZT, CAZ, CIP, COL, CTX, ETP, FEP, FOS, FOX, IMP, LEV, MRP, NAL, NET, PIP, TO, TZP | — | MB | ||
| 169 | Hepatic | AMX, AMC, AZT, CAZ, CIP, CTX, ETP, FEP, FOS, FOX, IMP, LEV, MRP, NAL, PIP, TGC, TO, TZP | — | MB | |||
| 171 | — | Renal | AMX, AMC, AZT, CTX, CAZ, CIP, ETP, FEP, FOS, FOX, GN, LEV, NAL, NET, PIP, TO, TGC, TZP | — | NB | ||
| 172 | Renal | AMX, AMC, AZT, CTX, CAZ, CIP, ETP, FEP, FOS, FOX, LEV, NAL, PIP, SXT, TGC, TZP | — | NB | |||
| 198 | — | Renal | AMX, AMC, AZT, CTX, CIP, LEV, NAL, NET, PIP, SXT, TO | MRHA | WB | ||
| 199 | Renal | AMX, AMC, AZT, CTX, CIP, LEV, NAL, NET, PIP, SXT, TO | MRHA | WB |
aAMX, amoxicillin; AMC, amoxicillin-clavulanic acid; AMK; amikacin; AZT, aztreonam; CAZ, ceftazidime; CIP, ciprofloxacin; COL, colistin; CTX, cefotaxime; ERT, ertapenem; FEP, cefepime; FOS, fosfomycin; FOX, cefoxitin; GN, gentamicin; IMP, imipenem; LEV, levofloxacin; MRP, meropenem; NAL, nalidixic acid; NET, netilmicin; PIP, piperacillin; SXT, trimethoprim–sulfamethoxazole;TIG, tigecycline TO, tobramycin; TZP, piperacillin-tazobactam. bMRHA, mannose-resistant hemagglutination. cBiofilm formation: NB, non-biofilm; WB, weak; MB, moderate; SB, strong.